Literature DB >> 30062926

A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses.

Sarah T C Elliott1, Amelia A Keaton1, Jacqueline D Chu1, Charles C Reed2, Bradley Garman2, Ami Patel1, Jian Yan2, Kate E Broderick2, David B Weiner1.   

Abstract

Influenza A H3N2 viruses circulate globally, leading to substantial morbidity and mortality. Commercially available, antigen-matched influenza vaccines must be updated frequently to match dynamic sequence variability in immune epitopes, especially within viral influenza A H3N2 hemagglutinin (H3). In an effort to create comprehensive immune responses against H3N2, four micro-consensus antigens were designed to mimic the sequence and antigenic diversity of H3. Synthetic plasmid DNA constructs were developed to express each micro-consensus immunogen and combined into a multi-antigen DNA vaccine cocktail, pH3HA. Facilitated delivery of pH3HA via intramuscular electroporation in mice induced comprehensive, potent humoral responses against diverse seasonal H3N2 viruses that circulated between 1968 and the present. Vaccination with pH3HA also induced an antigen-specific cellular cytokine response. Mice immunized with pH3HA were protected against lethal challenge using two distinct H3N2 viruses, highlighting the heterologous protection afforded by synthetic micro-consensus immunogens. These findings warrant further study of the DNA vaccine micro-consensus platform for broad protection against influenza viruses.

Entities:  

Keywords:  plasmid DNA vaccine; seasonal influenza

Mesh:

Substances:

Year:  2018        PMID: 30062926      PMCID: PMC6152850          DOI: 10.1089/hum.2018.102

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  32 in total

1.  Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

Authors:  Dominick J Laddy; Jian Yan; Natasha Corbitt; Gary P Kobinger; David B Weiner
Journal:  Vaccine       Date:  2007-01-30       Impact factor: 3.641

2.  Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution.

Authors:  Elodie Ghedin; Naomi A Sengamalay; Martin Shumway; Jennifer Zaborsky; Tamara Feldblyum; Vik Subbu; David J Spiro; Jeff Sitz; Hean Koo; Pavel Bolotov; Dmitry Dernovoy; Tatiana Tatusova; Yiming Bao; Kirsten St George; Jill Taylor; David J Lipman; Claire M Fraser; Jeffery K Taubenberger; Steven L Salzberg
Journal:  Nature       Date:  2005-10-05       Impact factor: 49.962

3.  A statistically defined endpoint titer determination method for immunoassays.

Authors:  A Frey; J Di Canzio; D Zurakowski
Journal:  J Immunol Methods       Date:  1998-12-01       Impact factor: 2.303

4.  Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine.

Authors:  Jian Yan; Matthew P Morrow; Jaemi S Chu; Trina Racine; Charles C Reed; Amir S Khan; Kate E Broderick; J Joseph Kim; Gary P Kobinger; Niranjan Y Sardesai; David B Weiner
Journal:  Vaccine       Date:  2018-05-24       Impact factor: 3.641

Review 5.  Electroporation delivery of DNA vaccines: prospects for success.

Authors:  Niranjan Y Sardesai; David B Weiner
Journal:  Curr Opin Immunol       Date:  2011-04-27       Impact factor: 7.486

6.  Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.

Authors:  Dominick J Laddy; Jian Yan; Amir S Khan; Hanne Andersen; Amanda Cohn; Jack Greenhouse; Mark Lewis; Jody Manischewitz; Lisa R King; Hana Golding; Ruxandra Draghia-Akli; David B Weiner
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

7.  Differences in clinical features between influenza A H1N1, A H3N2, and B in adult patients.

Authors:  Masahide Kaji; Aya Watanabe; Hisamichi Aizawa
Journal:  Respirology       Date:  2003-06       Impact factor: 6.424

8.  Estimates of global seasonal influenza-associated respiratory mortality: a modelling study.

Authors:  A Danielle Iuliano; Katherine M Roguski; Howard H Chang; David J Muscatello; Rakhee Palekar; Stefano Tempia; Cheryl Cohen; Jon Michael Gran; Dena Schanzer; Benjamin J Cowling; Peng Wu; Jan Kyncl; Li Wei Ang; Minah Park; Monika Redlberger-Fritz; Hongjie Yu; Laura Espenhain; Anand Krishnan; Gideon Emukule; Liselotte van Asten; Susana Pereira da Silva; Suchunya Aungkulanon; Udo Buchholz; Marc-Alain Widdowson; Joseph S Bresee
Journal:  Lancet       Date:  2017-12-14       Impact factor: 79.321

9.  Update: Influenza activity--United States, September 28, 2014-February 21, 2015.

Authors:  Tiffany D'Mello; Lynnette Brammer; Lenee Blanton; Krista Kniss; Sophie Smith; Desiree Mustaquim; Craig Steffens; Rosaline Dhara; Jessica Cohen; Sandra S Chaves; Lyn Finelli; Joseph Bresee; Teresa Wallis; Xiyan Xu; Anwar Isa Abd Elal; Larisa Gubareva; David Wentworth; Julie Villanueva; Jackie Katz; Daniel Jernigan
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-03-06       Impact factor: 17.586

10.  Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness - United States, February 2018.

Authors:  Brendan Flannery; Jessie R Chung; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Angie Foust; Wendy Sessions; LaShondra Berman; John R Barnes; Sarah Spencer; Alicia M Fry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-02-16       Impact factor: 17.586

View more
  6 in total

1.  Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.

Authors:  James D Allen; Ted M Ross
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

Review 2.  Better influenza vaccines: an industry perspective.

Authors:  Juine-Ruey Chen; Yo-Min Liu; Yung-Chieh Tseng; Che Ma
Journal:  J Biomed Sci       Date:  2020-02-14       Impact factor: 8.410

3.  Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses.

Authors:  James D Allen; Ted M Ross
Journal:  Sci Rep       Date:  2021-03-02       Impact factor: 4.379

Review 4.  Progress towards the Development of a Universal Influenza Vaccine.

Authors:  Wen-Chien Wang; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Viruses       Date:  2022-07-30       Impact factor: 5.818

Review 5.  Next-generation influenza vaccines: opportunities and challenges.

Authors:  Chih-Jen Wei; Michelle C Crank; John Shiver; Barney S Graham; John R Mascola; Gary J Nabel
Journal:  Nat Rev Drug Discov       Date:  2020-02-14       Impact factor: 84.694

Review 6.  Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine.

Authors:  Brianna L Bullard; Eric A Weaver
Journal:  Vaccines (Basel)       Date:  2021-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.